Phase 1b trial on the safety, tolerability and immunogenicity of anti-amyloid vaccine ALZ-101 in subjects with MCI or mild AD

ALZ-101 - Alzinova

https://alz.confex.com/alz/2024/meetingapp.cgi/Paper/95440

Henrik Zetterberg, MD, PhD1; Juha O. Rinne, MD, PhD2; Anders Sandberg, PhD3; Zsófia Lovró, MD4; Mika Scheinin, PhD, MD4; Stefan Pierrou, PhD3; Kirsten Harting, MD, MBA3

Jun 20, 2024